-
Start Preamble
ACTION:
Notice of registration.
SUMMARY:
The registrant listed below has applied for and been granted registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule II controlled substances.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on a previously published notice is listed below. No comments or objections were submitted for the notice.
Company FR docket Published Janssen Pharmaceuticals, Inc 83 FR 55205 November 2, 2018. The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.
Start SignatureDated: January 7, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-02868 Filed 2-20-19; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 02/21/2019
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of registration.
- Document Number:
- 2019-02868
- Pages:
- 5500-5500 (1 pages)
- Docket Numbers:
- Docket No. DEA-392
- PDF File:
- 2019-02868.pdf